R&D | March 26, 2026
Zealand Pharma launches major US research hub in Cambridge, Massachusetts
The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities
The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities
SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors
The initiative will be led by David Baker, 2024 Nobel Prize winner in Chemistry, IPD director, professor of biochemistry, and HHMI Investigator at the University of Washington
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
Both companies say the collaboration is driven by a shared mission to improve patient outcomes by aligning every step of the diagnostic process
This linear, covalently closed, double-stranded DNA offers a rapid, cell-free alternative to traditional plasmid DNA, addressing a critical bottleneck in nucleic acid therapeutics development
The study included four independent genetic substudies targeting obesity caused by heterozygous variants in the POMC/PCSK1, LEPR, SRC1 (NCOA1), and SH2B1 genes
The partnership is designed to close the gap between classroom learning and real-world pharmaceutical practice
The Flonase Allergy Relief Nasal Spray, 50 mcg per spray market achieved annual sales of approximately $384.7 million
The move opens Japan’s advanced life science market to Epigenica’s high-throughput epigenetic profiling kits
Subscribe To Our Newsletter & Stay Updated
